Arrowhead’s “We'll Get There Soon” campaign reflects its potential benefits of plozasiran. The campaign logo uses “500N” ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday, the ...

While the deal would not weigh heavily on Roche’s own production operations, “it could be a problem for other smaller players if there is a restriction in terms of how many CMOs are available ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant Catalent by the end of the year. A dozen consumer groups and trade ...

Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss pharma’s top-selling drug Entresto. In a court decision filed this ...

SpectronRx first signed a memorandum of understanding with SCK CEN for the new facility in 2023. With the new agreement, the CDMO is now officially on deck to provide equipment and offer up its ...

With Gilead Sciences sprinting to a likely approval next year for its long-acting pre-exposure prophylaxis (PrEP) drug for HIV, the California company has a chance to one-up GSK. While the British ...